Home/Get Matched/NCT03826524
Phase 4Recruiting
View on ClinicalTrials.gov

Testing Epinephrine for out-of-hospital cardiac arrest

Official title: Epinephrine Dose: Optimal Versus Standard Evaluation Trial

CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial)

Condition: Cardiac Arrest, Out-Of-HospitalSponsor: Unity Health TorontoTarget enrollment: 3790
  • Phase 4
  • 2 groups
  • Sites in Victoria, Brampton and 6 more cities
  • Recruiting
British Columbia Emergency Health Services (BCEHS), Victoria, British ColumbiaPeel Regional Paramedic Services, Brampton, OntarioMiddlesex-London Paramedic Service, London, OntarioHalton Region Paramedic Services, Oakville, OntarioOttawa Paramedic Services, Ottawa, OntarioSuperior North Emergency Medical Services, Thunder Bay, OntarioEssex-Windsor Emergency Health Services, Windsor, OntarioMedavie Health Services West, Saskatoon, Saskatchewan

Interventions

  • Medication

    Epinephrine

    Epinephrine 1mg 1:10000 (10cc) per dose

Canadian Sites (8)

8 of 8 recruiting

  • British Columbia Emergency Health Services (BCEHS)

    Victoria, British Columbia

    Recruiting

  • Peel Regional Paramedic Services

    Brampton, Ontario

    Recruiting

  • Middlesex-London Paramedic Service

    London, Ontario

    Recruiting

Eligibility Criteria

See who this study is looking for9 criteria

The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.

Inclusion

  • +Out-of-hospital cardiac arrest treated by paramedics
  • +Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or witnessed by EMS (paramedic or fire)
  • +Established intravenous vascular access

Exclusion

  • −Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.)
  • −Known allergy or sensitivity to epinephrine
  • −Known or apparent age \<18 years
  • −Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics
  • −Administration of intramuscular, endotracheal tube, or intraosseous epinephrine
  • −Prisoners or persons in police custody
5 concepts to explore on this page · up to 1,300 pointsTap any term to learn what it means.

In plain language

Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.

Learning 
What this study is

This study is testing a treatment for a condition.

Phase 4Phase 4A study of a treatment that is already approved and in use.Read more → — a study of a treatment already approved for use, following it in everyday practice.

From the trial registry

Built from these fields:

  • designModule.designInfo.primaryPurpose
  • designModule.phases
Who receives what

There are 2 groups in this study.

Groups A and B, the comparison group, receive Epinephrine.

Registry label: A: Low Dose Epinephrine · B: Standard Dose Epinephrine

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].label
  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
How the study is run

Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.

You, the study team, and the people analysing the results would all be kept unaware of which group you are in until the study ends.

From the trial registry

Built from these fields:

  • designModule.designInfo.allocation
  • designModule.designInfo.maskingInfo.masking
Is there a placebo?

This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.

One group receives an existing treatment, so the two can be compared.

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for

The study lists a minimum age of 18 years, with no upper limit given.

The study is open to people of any sex.

The study does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.

These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.

From the trial registry

Built from these fields:

  • eligibilityModule.minimumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How big and how long

The study aims to enrol about 3,790 people.

The study is currently expected to finish around December 2028.

The main measurement is taken over: Through study completion (up to 5 years).

From the trial registry

Built from these fields:

  • designModule.enrollmentInfo.count
  • statusModule.completionDateStruct.date
  • outcomesModule.primaryOutcomes[].timeFrame
What the study measures

Survival to hospital discharge — measured over Through study completion (up to 5 years).

From the trial registry

Built from these fields:

  • outcomesModule.primaryOutcomes[].measure
  • outcomesModule.primaryOutcomes[].timeFrame

Source: NCT03826524 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.

Not medical advice. What do these terms mean?

What is being tested — in plain terms

About EpinephrineDrug

Epinephrine 1mg 1:10000 (10cc) per dose

From the trial registry — its own words, unedited.

What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.

Read the full explanation → · in clinical review

Common questions

Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.

Am I eligible for this trial?

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.

What the study lists: a minimum age of 18 years.

The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.

The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.

See how your details line up — get matched
From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.eligibilityCriteria
Is there a placebo?

This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.

One group receives an existing treatment so the two can be compared.

Save this trial to share with your doctor
From the trial registry
  • armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?

You, the study team, and the people analysing the results would all be kept unaware of which group you are in until the study ends.

Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.

Save this trial to share with your doctor
From the trial registry
  • designModule.designInfo.maskingInfo.masking
  • designModule.designInfo.allocation
Who can join?

The study lists a minimum age of 18 years, with no upper limit given.

It is open to people of any sex.

It does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.

See how your details line up — get matched
From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How long would this take?

The study's main measurement is taken over: Through study completion (up to 5 years).

The study as a whole is currently expected to finish around 2028-12.

How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.

Ask the study team directly
From the trial registry
  • outcomesModule.primaryOutcomes[].timeFrame
  • statusModule.completionDateStruct.date
How many people are taking part?

The study aims to enrol about 3,790 people.

Save this trial to share with your doctor
From the trial registry
  • designModule.enrollmentInfo.count
Where is this happening?

This study lists 8 locations, including: Victoria, British Columbia, Canada; Brampton, Ontario, Canada; London, Ontario, Canada; Oakville, Ontario, Canada; Ottawa, Ontario, Canada; Thunder Bay, Ontario, Canada, and 2 more.

Sites can open and close during a study, so confirm with the team before travelling.

Ask the study team directly
From the trial registry
  • trial_locations

About This Trial

The objective of this randomized controlled trial is to evaluate the effectiveness of a low cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during resuscitation from ventricular fibrillation (VF) or ventricular tachycardia (VT) in adult out-of-hospital cardiac arrest (OHCA) patients.

Think this trial might be right for you?

Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.

See if this trial could fit you

This page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.

HomePrivacyTerms